LIB Therapeutics LLC Report issue

For profit Phase 3
Founded: Cincinnati OH United States (2017)

Organization Overview

First Clinical Trial
2017
NCT03545438
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

LIB Therapeutics | LIB Therapeutics LLC

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hypercholesterolemia (Phase 3)

Hyperlipoproteinemia Type II (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 11
  • # of Trial APIs: 4